Show simple item record

dc.contributor.authorAdeniji, Adetomiwa A.
dc.contributor.authorKnoll, Kirsten E.
dc.contributor.authorLoots, Du Toit
dc.date.accessioned2020-05-22T08:51:44Z
dc.date.available2020-05-22T08:51:44Z
dc.date.issued2020
dc.identifier.citationAdeniji, A.A. et al. 2020. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus. Applied microbiology and biotechnology, 104:5633-5662. [https://doi.org/10.1007/s00253-020-10606-y]en_US
dc.identifier.issn0175-7598
dc.identifier.issn1432-0614 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/34668
dc.identifier.urihttps://link.springer.com/article/10.1007/s00253-020-10606-y
dc.identifier.urihttps://doi.org/10.1007/s00253-020-10606-y
dc.description.abstractThe latest WHO report estimates about 1.6 million global deaths annually from TB, which is further exacerbated by drug-resistant (DR) TB and comorbidities with diabetes and HIV. Exiguous dosing, incomplete treatment course, and the ability of the tuberculosis bacilli to tolerate and survive current first-line and second-line anti-TB drugs, in either their latent state or active state, has resulted in an increased prevalence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant TB (TDR-TB). Although a better understanding of the TB microanatomy, genome, transcriptome, proteome, and metabolome, has resulted in the discovery of a few novel promising anti-TB drug targets and diagnostic biomarkers of late, no new anti-TB drug candidates have been approved for routine therapy in over 50 years, with only bedaquiline, delamanid, and pretomanid recently receiving tentative regulatory approval. Considering this, alternative approaches for identifying possible new anti-TB drug candidates, for effectively eradicating both replicating and non-replicating Mycobacterium tuberculosis, are still urgently required. Subsequently, several antibiotic and non-antibiotic drugs with known treatment indications (TB targeted and non-TB targeted) are now being repurposed and/or derivatized as novel antibiotics for possible use in TB therapy. Insights gathered here reveal that more studies focused on drug-drug interactions between licensed and potential lead anti-TB drug candidates need to be prioritized. This write-up encapsulates the most recent findings regarding investigational compounds with promising anti-TB potential and drugs with repurposing potential in TB therapyen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectAdjunct drugsen_US
dc.subjectAnti-tuberculosis therapyen_US
dc.subjectDrug resistanceen_US
dc.subjectMonotherapyen_US
dc.subjectMycobacterium tuberculosisen_US
dc.subjectProdrugsen_US
dc.titlePotential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectusen_US
dc.typeArticleen_US
dc.contributor.researchID10799508 - Loots, Du Toit
dc.contributor.researchID26352842 - Adeniji, Adetomiwa A.
dc.contributor.researchID25773267 - Knoll, E.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record